The well‐known BCR‐ABL fusion, in particular, has become a crucial reference standard for the diagnosis and treatment of chronic myeloid leukemia (CML).[1] The chromosomal rearrangement involving the TMPRSS2‐ERG gene fusion, which is universally present in prostate cancer, shows potential for detecting aggressive forms of the disease.[2] Additionally, there are EML4‐ALK in lung adenocarcinomas,[3]FGFR3‐TACC3 in glioblastoma multiforme (GBM),[4] among others. This evidence concerns the gene FGFR3 and chronic myelogenous leukemia, BCR-ABL1 positive.